THE LUSTGARTEN FOUNDATION AND BREAK THROUGH CANCER ANNOUNCE NEW CLINICAL TRIAL EVALUATING KRAS-TARGETED IMMUNOTHERAPY STRATEGY FOR PANCREATIC CANCER

Newly recruiting Phase 1 study will evaluate a next-generation KRAS-targeted immunotherapy, revealing how pancreatic tumor microenvironment shapes treatment response UNIONDALE, N.Y., Aug. 10, 2026 /PRNewswire/ -- The Lustgarten Foundation and Break Through Cancer today announced the...